Moss D J, Khanna R, Bharadwaj M
Infectious Disease and Immunology Division, Queensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Bancroft Centre, Herston, Qld, Australia.
Dev Biol (Basel). 2002;110:67-71.
Epstein-Barr virus (EBV) infection is associated with infectious mononucleosis (IM) and with a number of human malignancies including nasopharyngeal carcinoma (NPC), Hodgkin's disease (HD) and immunoblastic lymphoma (IL). Their potential for immunotherapeutic treatment by cytotoxic T cells (CTL) is dependent on the degree of EBV antigen expression, with the best prospect revolving around IM where a vaccine is under development and IL of transplant patients where adoptive transfer of in vitro reactivated CTL has already been demonstrated to be effective. The opportunities for effective immunotherapy in the treatment of NPC is reduced since the available targets are limited to relatively non-immunogenic proteins. Perhaps more importantly, the development of immunotherapeutics is not considered a realistic commercial proposition. The best chance of developing an effective vaccine is to exploit the similarities in phenotype between HD and NPC since a vaccine to the former is likely to have more commercial appeal.
爱泼斯坦-巴尔病毒（EBV）感染与传染性单核细胞增多症（IM）以及多种人类恶性肿瘤相关，包括鼻咽癌（NPC）、霍奇金病（HD）和免疫母细胞淋巴瘤（IL）。细胞毒性T细胞（CTL）对其进行免疫治疗的潜力取决于EBV抗原的表达程度，最有前景的是针对正在研发疫苗的IM，以及已证明体外重新激活的CTL过继转移有效的移植患者IL。由于可用靶点仅限于相对缺乏免疫原性的蛋白质，因此在NPC治疗中进行有效免疫治疗的机会减少。也许更重要的是，免疫治疗药物的开发不被认为是一个现实的商业提议。开发有效疫苗的最佳机会是利用HD和NPC之间表型的相似性，因为针对前者的疫苗可能更具商业吸引力。
